YOLFTbeta
Zelluna ASA

Zelluna ASA

ZLNA · OL · Healthcare / Biotechnology

15.65NOK-0.45 (-2.80%)

Price History

Full chart

Market Stats

Previous Close16.10
Open16.10
Day Range15.30 – 16.10
52-Week Range8.20 – 35.80
Volume17.85K
Market Cap573.32M
P/E (TTM)0.00
Forward P/E0.00
EPS-4.90
Dividend Yield0.00%
50-Day Avg21.93
200-Day Avg19.58

About

Zelluna ASA, a clinical-stage biotechnology company, engages in the development of T-cell receptor guided natural killer cell therapies in Norway. It develops ZI-MA4-1 which is in Phase I clinical trial for the treatment of non-small cell lung cancer, ovarian, and head and neck synovial sarcoma; ZI-KL1-1 which is in preclinical trial for the treatment of breast, gastric, lung, pancreatic, and cervix cancers; and ZI-PR-1 which is in discovery stage for the treatment of solid tumors. The company was incorporated in 2016 and is headquartered in Oslo, Norway.

Company Details

  • SectorHealthcare
  • IndustryBiotechnology
  • CEOMr. Namir Hassan Ph.D.
  • Employees15
  • HeadquartersOslo Cancer Cluster Innovation Park, Oslo, Norway, 0379, Norway
  • Websitehttps://zelluna.com

Leadership

  • Mr. Namir Hassan Ph.D.Chief Executive Officer
  • Mr. Geir Christian Melen MScChief Financial Officer · b. 1965
  • Mr. Anders Holm Ph.D.Chief Operating Officer & Head of Business Development
  • Ms. Emilie Gauthy Ph.D.Chief Technology Officer
  • Ms. Luise Weigand Ph.D.Chief Scientific Officer
  • Ms. Julia Ino Ph.D.Head of Project Management & Clinical Project Manager
  • Mr. Anders TuvCo-Founder & Chairman
  • Mr. Jens Egil Torbjorn Bjorheim M.D., Ph.D.Chief Medical Officer
  • Orla Mc CallionHead of Regulatory Affairs & QA

Financials

Income Statement

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Revenue00053.00K0
Growth (%)-----100.00%
Operating Income-163.83M-183.63M-215.74M-109.57M-143.83M
Operating Margin----206739.62%-
EBITDA--180.98M-212.97M-101.28M-135.78M
EBITDA Margin----191092.45%-
Net Income-164.72M-167.79M-189.24M-105.16M-140.71M
Net Income Margin----198418.87%-
R&D96.73M95.17M123.83M88.68M58.22M
R&D as % of Total Revenue---167324.53%-
Interest Expense333.00K-3.14M1.39M1.41M
Interest Expense % of Total Revenue---2613.21%-

Balance Sheet

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Total Assets655.54M509.67M349.04M50.42M103.50M
Total Liabilities62.38M60.32M69.65M14.38M17.65M
Total Equity593.15M449.35M279.39M36.04M85.86M
Cash574.17M423.49M264.86M26.64M75.17M

Cash Flow

Currency: NOK2021-12-312022-12-312023-12-312024-12-312025-12-31
Operating Cash Flow-125.83M-167.69M-189.83M-99.95M-149.03M
Investing Cash Flow-8.69M14.03M-7.39M94.78M
Financing Cash Flow-3.58M-1.85M7.82M105.98M
Capital Expenditure85.00K195.00K25.00K10.36M359.00K
Free Cash Flow-125.91M-167.89M-189.85M-163.42M-149.39M
FCF to OCF100.07%100.12%100.01%163.49%100.24%

Earnings

Report DateNov 27, 2019Feb 26, 2020Jun 3, 2020Sep 2, 2020Dec 2, 2020Mar 3, 2021Jun 2, 2021Aug 20, 2021Nov 11, 2021Feb 17, 2022May 12, 2022Aug 19, 2022Nov 10, 2022Feb 16, 2023May 11, 2023Aug 22, 2023Nov 8, 2023Feb 14, 2024May 7, 2024Aug 21, 2024Nov 6, 2024Jan 31, 2025May 9, 2025Aug 20, 2025Nov 6, 2025Feb 13, 2026May 7, 2026Aug 20, 2026Nov 5, 2026
EPS Estimate-----------------------------
EPS Actual-6.19-9.10-10.89-11.94-9.61-7.69-10.57-11.39-13.53-15.27-10.69-6.54-11.19-20.55-9.92-12.61-16.23-16.26-6.61-13.01-7.51-31.31-3.66-1.84-1.92-1.46-0.78-0.72-
Surprise-----------------------------
Timing--------------------------Pre-marketPre-marketPre-market

Key Statistics & Ratios

Market Cap573.32M
Enterprise Value512.03M
Trailing P/E0.00
Forward P/E0.00
Price / Sales71665.23
Price / Book5.65
EPS-4.90
Book Value2.55
Revenue (TTM)8.00K
Gross Profit (TTM)8.00K
EBITDA-107.98M
Profit Margin0.00%
Operating Margin-1383137.50%
Return on Equity-115.40%
Return on Assets-59.97%
Shares Outstanding29.86M
Shares Float11.63M
Dividend Yield0.00%
Dividend Rate0.00
Payout Ratio0.00%

Stock Splits

  • Apr 1, 20251:10